Compare LyondellBasell Industries NV (LYB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs TransMedics Group Inc — how do they compare? LyondellBasell Industries NV trades at $61.86 (market cap $19.60B), while TransMedics Group Inc trades at $74.72 (market cap $2.54B). The key difference: LyondellBasell Industries NV is far larger — about 7.7× TransMedics Group Inc's market cap, and LyondellBasell Industries NV pays a 6.78% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| LYB | TMDX | |
|---|---|---|
Market Cap | $19.60B | $2.54B |
Sector | Basic Materials | Technology |
52-Week High | $82.38 | $150.42 |
52-Week Low | $42.28 | $61.99 |
Enterprise Value | $31.22B | $2.94B |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.78, up 2.69% today, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals: revenue declined to $30.15B in 2025 with a net loss of $745M, yet valuation ratios like P/S of 0.64 appear attractive. Recent news highlights partnerships for sustainable packaging, while cash flow remains positive. Analysts are divided with a consensus price target of $73.11, suggesting 20% upside potential from current levels.
Outlook: LYB offers value appeal with low P/S and dividend yield, but faces profitability challenges and industry headwinds. Risks include volatile earnings and high debt. The stock is suitable for value investors tolerant of cyclical downturns, with catalysts from restructuring and sustainability initiatives.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
